The importance of individually customized treatment for CLL patients
The problem of treating AML with CD123-targeting drugs
The regulation of biosimilars
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Targeted agents in acute myeloid leukemia in elderly patients